Published in Medical Letter on the CDC and FDA, September 25th, 2005
Fibrillex is for the treatment of Amyloid A (AA) Amyloidosis. Neurochem plans to complete the submission of the NDA at or around year-end. As announced earlier, the FDA has agreed to file and review this NDA. AA Amyloidosis is a serious medical condition for which no specific treatment...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA